Tess V. Dupre

Tess V. Dupre

Auto-generated profile, based on publicly available information

Tess V. Dupre

Department of Pharmacology and Toxicology, University of Louisville, Louisville, Kentucky

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2016 in American Journal of Physiology-Renal Physiology
Verified
Journal Article
Closed access
PDF file
CSCierra N. Sharp
Cierra N. Sharp
MDMark A. Doll
Mark A. Doll
TDTess V. Dupre
Tess V. Dupre
PSParag P. Shah
Parag P. Shah
MSMarimuthu Subathra
Marimuthu Subathra
LSLeah J. Siskind
Leah J. Siskind
Cisplatin, a chemotherapeutic used for the treatment of solid cancers, has nephrotoxic side effects leading to acute kidney injury (AKI). Cisplatin cannot be given to patients that have comorbidities that predispose them to an increased risk for AKI. Even without these comorbidities, 30% of patients administered cisplatin will develop kidney injury, requiring the oncologist to withhold or reduce the next dose, leading to a less effective therapeutic regimen. Although recovery can occur after one episode of cisplatin-induced AKI, longitudinal studies have indicated that multiple episodes of AKI lead to the development of chronic kidney disease, an irreversible disease with no current treatment. The standard mouse model of cisplatin-induced AKI consists of one high dose of cisplatin (>20 mg/kg) that is lethal to the animal 3 days later. This model does not accurately reflect the dosing regimen patients receive nor does it allow for the long-term study of kidney function and biology. We have developed a repeated dosing model whereby cisplatin is given once a week for 4 wk. Comparison of the repeated dosing model with the standard dosing model demonstrated that inflammatory cytokines and chemokines were induced in the repeated dosing model, but levels of cell death were lower in the repeated dosing model. The repeated dosing model had increased levels of fibrotic markers (fibronectin, transforming growth factor-β, and α-smooth muscle actin) and interstitial fibrosis. These data indicate that the repeated dosing model can be used to study the AKI to chronic kidney disease progression as well as the mechanisms of this progression.

7 February 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
PSParag P. Shah
Parag P. Shah
TDTess V. Dupre
Tess V. Dupre
LSLeah J. Siskind
Leah J. Siskind
Levi BeverlyLevi Beverly
Levi Beverly
Common cytotoxic chemotherapeutics induce epithelial-mesenchymal transition (EMT) downstream of ER stress

1 July 2017 in Journal of Lipid Research
Verified
Journal Article
Open access
PDF file
TDTess V. Dupre
Tess V. Dupre
MDMark A. Doll
Mark A. Doll
PSParag P. Shah
Parag P. Shah
CSCierra N. Sharp
Cierra N. Sharp
DSDeanna Siow
Deanna Siow
LSLeah J. Siskind
Leah J. Siskind
Acute kidney injury (AKI), resulting from chemotherapeutic agents such as cisplatin, remains an obstacle in the treatment of cancer. Cisplatin-induced AKI involves apoptotic and necrotic cell death, pathways regulated by sphingolipids such as ceramide and glucosylceramide. Results from this study indicate that C57BL/6J mice treated with cisplatin had increased ceramide and hexosylceramide levels in the renal cortex 72 h following cisplatin treatment. Pretreatment of mice with inhibitors of acid sphingomyelinase and de novo ceramide synthesis (amitriptyline and myriocin, respectively) prevented accumulation of ceramides and hexosylceramide in the renal cortex and protected from cisplatin-induced AKI. To determine the role of ceramide metabolism to hexosylceramides in kidney injury, we treated mice with a potent and highly specific inhibitor of glucosylceramide synthase, the enzyme responsible for catalyzing the glycosylation of ceramides to form glucosylceramides. Inhibition of glucosylceramide synthase attenuated the accumulation of the hexosylceramides and exacerbated ceramide accumulation in the renal cortex following treatment of mice with cisplatin. Increasing ceramides and decreasing glucosylceramides in the renal cortex sensitized mice to cisplatin-induced AKI according to markers of kidney function, kidney injury, inflammation, cell stress, and apoptosis. Under conditions of high ceramide generation, data suggest that metabolism of ceramides to glucosylceramides buffers kidney ceramides and helps attenuate kidney injury.—Dupre, T. V., M. A. Doll, P. P. Shah, C. N. Sharp, D. Siow, J. Megyesi, J. Shayman, A. Bielawska, J. Bielawski, L. J. Beverly, M. Hernandez-Corbacho, C. J. Clarke, A. J. Snider, R. G. Schnellmann, L. M. Obeid, Y. A. Hannun, and L. J. Siskind. Inhibiting glucosylceramide synthase exacerbates cisplatin-induced acute kidney injury. J. Lipid Res. 2017. 58: 1439–1452.

19 February 2014 in Journal of Surgical Research
Verified
Journal Article
Closed access
PDF file
MZMatthew R. Zeiderman
Matthew R. Zeiderman
MEMichael E. Egger
Michael E. Egger
CKCharles W. Kimbrough
Charles W. Kimbrough
CEChristopher G. England
Christopher G. England
TDTess V. Dupre
Tess V. Dupre
LMLacey R. McNally
Lacey R. McNally

22 February 2016
Verified
Thesis
Closed access
PDF file
TDTess Dupre
Tess Dupre
In rodent models, suramin improves recovery following acute kidney injury (AKI). We hypothesized that suramin would be useful in protection against cisplatin-induced AKI. This hypothesis was tested by pre-treating C57BL/6j mice with suramin prior to cisplatin. Our data indicates that suramin protects the kidney from injury by decreasing cisplatininduced decreases in kidney function. Renal histology indicated that suramin significantly protected from cisplatin-induced AKI. Data indicate that suramin pretreatment attenuated mRNA expression of pro-inflammatory cytokines and chemokines following cisplatin treatment, while also decreasing markers of cell stress and cell death. We utilized the same experimental design with 10-month old FVB mice expressing mutant Kras driven lung adenocarcinomas. Assessment of lung histology and kidney function indicated that suramin protected mice from cisplatin-induced AKI and did not inhibit cisplatin’s anti-tumor efficacy. These results suggest that suramin shows great potential as a renoprotective agent for the treatment/ prevention of cisplatininduced AKI.

1 January 2018
Verified
Book Chapter
Closed access
TDT.V. Dupre
T.V. Dupre
CSC.N. Sharp
C.N. Sharp
LSL.J. Siskind
L.J. Siskind